glp-1 drugs and menopause Postmenopausal women on the medication tirzepatide (Zepbound) for obesity lost more weight if they were also using hormone therapy, a retrospective cohort study indicated. https://www.medpagetoday.com/endocrinology/menopause/119594 THE PCCA BLOG | Managing

Cardiovascular effects Heart rate increased in a dose-dependent manner during the first 24 weeks of treatment, with the largest average increase being approximately 6.7 beats per minute at the 12 mg dose

doi: 10.1172/jci.insight.99123 71 TsugayaMHayashiYSasakiSKojimaYKohriKMogamiTet al

Further studies are still needed to evaluate the benefits of GLP-1 receptor agonists in patients with polycystic ovary syndrome

The role of kinetic context in apparent biased agonism at GPCRs

Nevertheless, these few trials with davalintide illustrate how the calcitonin receptor system may constitute a target for the treatment of obesity and associated metabolic conditions such as NAFLD

GlaxoSmithKline Safety Advisory: Reminder letter regarding the discontinuation of Eperzan(albiglutide) 1st July 2018